Section Arrow
Quote
MIRM.NASDAQ
- Mirum Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/22 20:17 EST
Regular Hours
Last
 70.97
+1.81 (+2.62%)
Day High 
71.56 
Prev. Close
69.16 
1-M High
74.465 
Volume 
721.26K 
Bid
45
Ask
80
Day Low
68.955 
Open
69.38 
1-M Low
66.79 
Market Cap 
3.55B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 70.46 
20-SMA 70.58 
50-SMA 72.1 
52-W High 78.5445 
52-W Low 36.8801 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.84/0.09
Enterprise Value
3.87B
Balance Sheet
Book Value Per Share
5.68
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
336.89M
Operating Revenue Per Share
2.82
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OSRHOSR Holdings Inc.0.5626+0.1066+23.38%-- 
SGMOSangamo Therapeutics0.4234+0.0384+9.97%-- 
RXRXRecursion Pharmaceuticals4.17+0.32+8.31%-- 
CYPHCypherpunk Technologies Inc.2.28-0.66-22.45%-- 
ASBPAspire Biopharma Holdings Inc.0.0974-0.0003-0.31%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.